MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, RVP made $7,177,397 in revenue. -$4,282,781 in net income. Net profit margin of -59.67%.

Income Overview

Revenue
$7,177,397
Net Income
-$4,282,781
Net Profit Margin
-59.67%
EPS
-$0.14
Unit: Dollar
Revenue Breakdown
    • United States Sales
    • North And South America Sales Ex...
    • Other International Sales
Revenue Breakdown
    • Syringes
    • Easy Point Needles
    • Blood Collection Products
    • Other Products

Income Statement
2026-03-31
2025-09-30
2025-06-30
2025-03-31
Sales, net
7,177,397 10,085,723 10,445,733 8,295,173
Product
7,358,809 7,572,544 9,721,614 -
Royalty
656,996 827,275 831,209 -
Total cost of sales
8,015,805 8,399,819 10,552,823 8,297,084
Gross profit (loss)
-838,408 1,685,904 -107,090 -1,911
Sales and marketing
1,734,070 1,583,760 1,661,743 1,601,808
Research and development
170,416 199,462 160,049 191,192
General and administrative
3,425,024 3,556,724 3,201,955 2,881,841
Total operating expenses
5,329,510 5,339,946 5,023,747 4,674,841
Loss from operations
-6,167,918 -3,654,042 -5,130,837 -4,676,752
Litigation proceeds
--1,900,000 -
Other income - tia
1,477,730 1,516,268 1,471,235 1,482,819
Unrealized gain (loss) on debt and equity securities
192,172 2,383,779 1,555,676 -7,156,513
Loss on trading debt securities
--343 --
Interest and other income
295,124 147,663 140,526 158,946
Interest expense
20,441 20,585 22,257 23,455
Net loss before income taxes
-4,223,333 372,740 -85,657 -10,214,955
Provision for income taxes
1,837 1,693 1,814 285,761
Net loss
-4,225,170 371,047 -87,471 -10,500,716
Preferred stock dividend requirements
57,611 57,611 57,611 57,611
Net loss applicable to common shareholders
-4,282,781 313,436 -145,082 -10,558,327
Basic EPS
-0.14 0.01 0 -0.35
Diluted EPS
-0.14 0.01 0 -0.35
Basic Average Shares
29,937,159 29,937,159 29,937,159 29,937,159
Diluted Average Shares
29,937,159 29,937,159 29,937,159 29,937,159
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss applicableto common...-$4,282,781 (59.44%↑ Y/Y)Net loss-$4,225,170 (59.76%↑ Y/Y)Preferred stock dividendrequirements$57,611 (0.00%↑ Y/Y)Net loss beforeincome taxes-$4,223,333 (58.66%↑ Y/Y)Provision for income taxes$1,837 (-99.36%↓ Y/Y)Other income - tia$1,477,730 (-0.34%↓ Y/Y)Interest and other income$295,124 (85.68%↑ Y/Y)Unrealized gain (loss) ondebt and equity...$192,172 (102.69%↑ Y/Y)Syringes$5,131,053 (-26.28%↓ Y/Y)Easy Point Needles$470,573 (-52.15%↓ Y/Y)Blood CollectionProducts$340,462 (-0.98%↓ Y/Y)Other Products$6,237 (-18.83%↓ Y/Y)Easy Point Needles$435,888 (-55.68%↓ Y/Y)Syringes$419,362 (-93.97%↓ Y/Y)Other Products$600 (-92.19%↓ Y/Y)Syringes$251,858 (-96.38%↓ Y/Y)Easy Point Needles$86,744 (-91.18%↓ Y/Y)Blood CollectionProducts$34,470 (-89.97%↓ Y/Y)Other Products$150 (-98.05%↓ Y/Y)Loss from operations-$6,167,918 (-31.88%↓ Y/Y)Interest expense$20,441 (-12.85%↓ Y/Y)United States Sales$5,948,325 (-19.97%↓ Y/Y)North And SouthAmerica Sales Excluding...$855,850 (54.63%↑ Y/Y)Other InternationalSales$373,222 (20.64%↑ Y/Y)Total operatingexpenses$5,329,510 (14.00%↑ Y/Y)Gross profit (loss)-$838,408 (-43772.74%↓ Y/Y)Sales, net$7,177,397 (-13.48%↓ Y/Y)General andadministrative$3,425,024 (18.85%↑ Y/Y)Sales and marketing$1,734,070 (8.26%↑ Y/Y)Research and development$170,416 (-10.87%↓ Y/Y)Total cost of sales$8,015,805 (-3.39%↓ Y/Y)Product$7,358,809 (-3.05%↓ Y/Y)Royalty$656,996 (-7.00%↓ Y/Y)

RETRACTABLE TECHNOLOGIES INC (RVP)

RETRACTABLE TECHNOLOGIES INC (RVP)